A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration

Atherosclerosis

Volumn 160, Issue 1, 2002, Pages 155-160

  Maison, Patrick ^a,b   Mennen, Louise ^b   Sapinho, David ^b   Balkau, Beverley ^b   Sigalas, Jacques ^c   Chesnier, Marie Christine ^d   Eschwège, Evelyne ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM   (France)

^c Centre d'Examens de Sante   (France)

^d Centres d'Examens de Santé   (France)

Author keywords

Fibrates; Fibrinogen; Lipid lowering drug; Pharmacoepidemiology; Statins

Indexed keywords

ALCOHOL; CHOLESTEROL; FIBRIC ACID DERIVATIVE; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING HABIT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036147354     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00552-4     Document Type: Article

References (40)

1. Fibrinogen and cardivoascular risk
2. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
3. Fibrinogen and risk of cardiovascular disease: The Framingham Study
4. Effect of statins on risk of coronary disease. A meta-analysis of randomised controlled trials
5. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction
6. Effects of two different fibric acid derivates on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia
7. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia
8. Effects of pravastatin and simvastatin on plasma fibrinogen level and blood rheology in type II hyperliproteinemia
9. Atovarstatin: An effective lipid-modifying agent in familial hypercholesterolemia
10. Effect of atovarstatin on plasma fibrinogen
11. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients
12. Modulation of plasma fibrinogen levels by Ciprofibrate and Gemfibrozil in primary hyperlipidemia
13. Population correlates of plasma fibrinogen and factor VII, putative risk factors
14. Constitutional, biochemical and lifestyle correlates of fibrinogen and factor VII activity in Polish urban and rural populations
15. Determinants of population changes in fibrinogen and factor VII over 6 years. The Atherosclerosis Risk in Communities (ARIC) study
16. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population - II. Baseline data on the relation to blood pressure, blood glucose, uric acid and lipid fractions
17. An epidemiological survey from a network of French Health Examination Centres: D.E.S.I.R. (Epidemiological Data on the Insulin Resistance Syndrome)
18. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients
19. Change in lipid-lowering drug use in France according to cardiovascular risk level: Before and after statin introduction
20. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs
21. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids
22. Effects of long-term treatment with lovastatin on the clotting system and blood platelets
23. Lovastatin therapy in hypercholesterolemia: Effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology
24. Hypercoagulable state in patients with hypercholesterolemia: Effects of pravastatin
25. Control of plasma fibrinogen levels
26. Drugs affecting plasma fibrinogen levels
27. Fibrate-modulated expression of fibrinogen, plasminogen avtivator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes
28. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidemic patients
29. Lipoproteins and thrombosis: Effects of lipid lowering
30. Gender differences in the relation between fibrinogen, tissue-type plasminogen activator antigen and markers of insulin resistance: Effects of smoking
31. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
32. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Carphilly and Speedwell Collaborative Heart Disease studies
33. Fibrinogen as a risk factor for stroke and myocardial infarction
34. Plasma fibrinogen: A major coronary risk factor
35. Epidemiology of thrombotic-hemostatic factors and their associations with cardiovascular disease
36. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction
37. Elevated plasma fibrinogen: Cause or consequence of cardiovascular disease?
38. Secondary Prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease
39. Drug treatment of lipid disorders